83249-10-9

Basic information

• Product Name: Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid, MonoMethyl ester
• Synonyms: Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid, MonoMethyl ester;3-(Methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid;Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid, 1-Methyl ester;1,1'-Bicyclo[1,1,1]pentane-1,3-dicarboxylic acid monomethyl ester;3-(Methoxycarbonyl)Bicyclo[1.1.1]Pentane-1-Carboxylic Acid(WX120556)
• CAS NO: 83249-10-9
• Molecular Formula: C₈H₁₀O₄
• Molecular Weight: 170.1626
• Mol File: 83249-10-9.mol
• Article Data: 16

Chemical Properties

• Melting Point: 138-139 °C(Solv: chloroform (67-66-3); heptane (142-82-5))
• Boiling Point: 272.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.559±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.50±0.40(Predicted)
• CAS DataBase Reference: Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid, MonoMethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid, MonoMethyl ester(83249-10-9)
• EPA Substance Registry System: Bicyclo[1.1.1]pentane-1,3-dicarboxylic acid, MonoMethyl ester(83249-10-9)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 83249-10-9(Hazardous Substances Data)

Usage

Uses

Bicyclo[1.1.1]pentane-1,3-dicarboxylic Acid, 1-methyl Ester acts as a reagent for the synthesis and in the biopharmaceutical evaluation of imatinib analogs. Also functions as a reagent for the preparation and in biological evaluation of novel bicyclo[1.1.1]pentane-based acidic amino acids as glutamate receptors ligands It is a COVID19-related research product.

Upstream product

• 67-56-1 methanol 
• 56842-95-6 bicyclo<1.1.1>pentane-1,3-dicarboxylic acid 
• 5781-53-3 monomethyl oxalyl chloride 
• 35634-10-7 [1.1.1]propellane 
• 110371-22-7 methyl 3-(chlorocarbonyl)bicyclo<1.1.1>pentane-1-carboxylate 
• 83249-04-1 3-phenylbicyclo<1.1.1>pentane-1-carboxylic acid 
• 65862-03-5 methyl 3-phenyl-2,2-dichlorobicyclo<1.1.1>pentanecarboxylate 
• 105542-93-6 1-(1-hydroxyethyl)-3-(1-oxoethyl)bicyclo<1.1.1>pentane 
• 115913-30-9 1,1′-(bicyclo[1.1.1]pentane-1,3-diyl)bis(ethan-1-one) 
• 311-75-1 bicyclo[1.1.1]pentane 
• 115913-31-0 1,3-bis(chlorocarbonyl)bicyclo<1.1.1>pentane 
• 115913-32-1 dimethyl bicyclo<1.1.1>pentane-1,3-dicarboxylate 
• 83249-09-6 methyl 3-phenylbicyclo<1.1.1>pentane-1-carboxylate 

Downstream Products

• 56842-95-6 bicyclo<1.1.1>pentane-1,3-dicarboxylic acid 
• 83249-14-3 methyl 3-bromobicyclo<1.1.1>pentane-1-carboxylate 
• 141046-59-5 methyl 3-iodobicyclo<1.1.1>pentane-1-carboxylate 
• 131515-46-3 methyl 3-(1,4-benzoquinonyl)bicyclo<1.1.1>pentane-1-carboxylate 
• 83249-09-6 methyl 3-phenylbicyclo<1.1.1>pentane-1-carboxylate 
• 156329-62-3 3-(hydroxymethyl)bicyclo[1.1.1]pentane-1-carbonitrile 
• 1113001-63-0 2-(3-methoxycarbonylbicyclo[1.1.1]pentane)acetic acid 
• 1113001-76-5 3-(tert-butoxycarbonylmethyl)bicyclo[1.1.1]pentane-1-carboxylic acid 
• 1113001-78-7 tert-butyl (3-(hydroxymethyl)bicyclo[1.1.1]pentyl)acetate 
• 1113001-80-1 tert-butyl (3-formylbicyclo[1.1.1]pentane)acetate 
• 1113001-69-6 C₁₈H₂₂N₂O₃ 
• 1113001-71-0 C₁₈H₂₂N₂O₃ 
• 1113001-82-3 C₂₁H₂₈N₂O₃ 
• 1113001-84-5 C₂₁H₂₈N₂O₃ 

Relevant articles and documents

Large-Scale Synthesis and Modifications of Bicyclo[1.1.1]pentane-1,3-dicarboxylic Acid (BCP)

In flow photochemical addition of propellane to diacetyl allowed construction of the bicyclo[1.1.1]pentane (BCP) core in a 1 kg scale within 1 day. Haloform reaction of the formed diketone in batch afforded bicyclo[1.1.1]pentane-1,3-dicarboxylic acid in a

CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS

The present invention provides compounds of Formula (I): (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

A DNA toxicity dimer compound (by machine translation)

The invention discloses a DNA toxicity dimer compound, with the previous technology disclosed benzo hypnotic benzodiazepines compared with the conjugates, the cytotoxic compound display much higher in vivo therapeutic index (the maximum tolerance dose and the lowest effective dose of ratio). (by machine translation)